Multicenter Phase II study of rechallenge Cetuximab plus Irinotecan in heavily pretreated Wild type KRAS metastatic Colorectal cancer

ABSTRACT: Interventions: Cetuximab + Irinotecan therapy Cetuximab Weekly schedule 400mg/(initial dose):250mg/m2(Maintenance dose) every week or Bi-weekly schedule 500mg/m2 every 2 weeks Irinotecan 150mg/m2 every 2 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2625919 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR